How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,721 results for

Antibiotic Food Interactions

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. WHO consolidated guideline on self-care interventions for health: sexual and reproductive health and rights

Economic empowerment (e.g. housing, food security, ability to pay for health care) Social accountability Health services Access to justice Accountability Self-care for health and well-being Regulated quality products and interventionsxiii Executive summary SCOPE OF SELF-CARE INTERVENTIONS While self-care is important in all aspects of health, it is particularly important – and particularly challenging to manage – for populations negatively affected by gender, political, cultural and power dynamics

2019 World Health Organisation Guidelines

102. Paediatric Urology

scintigraphy in 49 patients with acute scrotal pain: a comparison with ultrasonography. Ann Nucl Med, 2001. 15: 225. 168. Karmazyn, B., et al. Duplex sonographic findings in children with torsion of the testicular appendages: overlap with epididymitis and epididymoorchitis. J Pediatr Surg, 2006. 41: 500. 169. Lau, P., et al. Acute epididymitis in boys: are antibiotics indicated? Br J Urol, 1997. 79: 797. 170. Abul, F., et al. The acute scrotum: a review of 40 cases. Med Princ Pract, 2005. 14: 177. 171 (...) in Europe: a registry-based study. World J Urol, 2015. 33: 2159. 189. Morera, A.M., et al. A study of risk factors for hypospadias in the Rhone-Alpes region (France). J Pediatr Urol, 2006. 2: 169. 190. Springer, A., et al. Worldwide prevalence of hypospadias. J Pediatr Urol, 2016. 12: 152 e1. 191. van der Zanden, L.F., et al. Exploration of gene-environment interactions, maternal effects and parent of origin effects in the etiology of hypospadias. J Urol, 2012. 188: 2354. 192. Fredell, L., et al

2019 European Association of Urology

103. Male Sexual Dysfunction

Hypertens, 2004. 17: 1135. 199. Kloner, R.A., et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol, 2004. 172: 1935. 200. McCullough, A.R., et al. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology, 2002. 60: 28. 201. Forgue, S.T., et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol, 2006. 61: 280. 202. Nichols, D.J (...) ., et al. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol, 2002. 53 Suppl 1: 5S. 203. Rosen, R.C., et al. Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: a multicenter, randomized, double-blind, placebo-controlled, at-home study. J Sex Med, 2004. 1: 193. 204. Montorsi, F., et al. Earliest time to onset of action leading

2019 European Association of Urology

105. Prostate Cancer

food and prostate cancer risk: systematic review and meta-analysis. Int J Food Sci Nutr, 2015. 66: 587. 42. Chen, P., et al. Lycopene and Risk of Prostate Cancer: A Systematic Review and Meta-Analysis. Medicine (Baltimore), 2015. 94: e1260. 43. Rowles, J.L., 3rd, et al. Processed and raw tomato consumption and risk of prostate cancer: a systematic review and dose-response meta-analysis. Prostate Cancer Prostatic Dis, 2018. 21: 319. 44. Ilic, D., et al. Lycopene for the prevention and treatment (...) . Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem, 2006. 52: 59. 157. Eggener, S.E., et al. Empiric antibiotics for an elevated prostate-specific antigen (PSA) level: a randomised, prospective, controlled multi-institutional trial. BJU Int, 2013. 112: 925. 158. Xue, J., et al. Comparison between transrectal and transperineal prostate biopsy for detection of prostate cancer: a meta-analysis and trial sequential

2019 European Association of Urology

107. Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

fracture with long-term alendronate was halved versus placebo (HR 0.50 [95% CI 0.31, 0.82]) (moderate SOE). Although women with femoral neck BMD -2.5 to -2 had a similar relative reduction in these fractures versus placebo (HR 0.54 [95% CI 0.28, 1.04]) (low SOE), a lower proportion of women with osteopenia had incident radiographic vertebral fractures, and results were not statistically significant. No tests of interaction were reported for these BMD stratified results. In a post hoc analysis, women (...) with osteoporosis had a reduced risk of incident hip fracture with long-term alendronate versus placebo, but women with osteopenia had no reduced risk (p- value for interaction not reported). 14 In additional post hoc analyses, some conducted in women with osteopenia, 22, 23 neither past nonvertebral fracture, 23 10-year major osteoporotic fracture probability calculated with femoral neck BMD, 24 nor pretreatment levels of bone turnover markers 25 significantly modified the effect of long-term alendronate

2019 Effective Health Care Program (AHRQ)

108. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease

, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform and then finalized and voted on by a group of specialists. Results: The consensus includes 41 statements focused on 6 main drug classes: antibiotics, 5-aminosalicylate, corticosteroids, immunosuppressants, biologic therapies, and other therapies. The group suggested against the use of antibiotics or 5-aminosalicylate as induction or maintenance ther- apies. Corticosteroid therapies (including (...) online in November Abbreviations used in this paper: CAG, Canadian Association of Gastroenterology; CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; CDEIS, Crohn’s Disease Endoscopic Index of Severity; CI, confidence interval; CPG, clinical practice guideline; CrI, credible intervals; CRP , C-reactive protein; CTE, computed tomography enterography; ECCO, European Crohn’s and Colitis Organisation; FDA, Food and Drug Administration; GRADE, Grading of Recommendation Assessment, Development

2019 Canadian Association of Gastroenterology

109. Recurrent Uncomplicated Urinary Tract Infections in Women

associated with increased risk of any adverse event (6 studies, RR 1.73, 95% CI 1.08 to 2.79, I 2 =0%; ARD 12%, 95% CI 1% to 22%) 131,134,135,138,144,147 and vaginitis (3 studies, RR 3.01, 95% CI 1.27 to 7.15, I 2 =0%; ARD 18%, 95% CI 0.05 to 0.32). 134,138,147 There was no interaction between the antibiotic used and risk of adverse events. There were no differences in risk of withdrawal due to adverse events (4 studies, RR 2.76, 95% CI 0.64 to 11.84, I 2 =0%) 131,134,138,143 or gastrointestinal adverse (...) of urinary tract infections (UTIs) in the operative or procedural setting. In this document, the term UTI will refer to acute bacterial cystitis unless otherwise specified. This document seeks to establish guidance for the evaluation and management of patients with rUTIs to prevent inappropriate use of antibiotics, decrease the risk of antibiotic resistance, reduce adverse effects of antibiotic use, provide guidance on antibiotic and non-antibiotic strategies for prevention, and improve clinical outcomes

2019 American Urological Association

110. Endoscope Disinfection

flexible endoscope reprocessor (AFER), which should comply with the relevant national standard or be approved by the U.S. Food and Drug Administration (FDA). The AFER may or may not have an automated cleaning cycle as well as the disinfection cycle. All connectors should be specifically designed for each endoscope model. Ensure that all channels are connected at the start and end of a cycle. The detachable components, including the air/water and suction valves, can be steam-sterilized or reprocessed (...) and mortality due to their antibiotic resistance. Outbreaks of CPE after endoscopy have been reported in several countries, often after endoscopic retrograde cholangiopancreatography (ERCP) [ ] but also following bronchoscopy [ ], gastroscopy [ – ], and flexible cystoscopy [ ]. Often microbiological surveillance identifies a single source for an outbreak of MDROs that can be traced to a culprit endoscope that has transmitted genetically similar bacteria on multiple occasions despite reprocessing. MDROs may

2019 World Gastroenterology Organisation

111. Registries for Evaluating Patient Outcomes: A User's Guide: Fourth Edition (Draft)

develop hypotheses, or identify patient populations that will be useful for product development, clinical trials design, and patient recruitment. The U.S. Food and Drug Administration (FDA) has noted that “through the creation of registries, a sponsor can evaluate safety signals identified from spontaneous case reports, literature reports, or other sources, and evaluate the factors that affect the risk of adverse outcomes such as dose, timing of exposure, or patient characteristics.” 13 Registries may

2019 Effective Health Care Program (AHRQ)

112. Management of Atopic Eczema

. INTRODUCTION 1 2. DIAGNOSIS 3 2.1 Diagnostic criteria 3 2.2 Supportive investigations 3 3. SEVERITY ASSESSMENT 4 4. CO-MORBIDITIES 4 5. AGGRAVATING/TRIGGERING FACTORS 7 5.1 Aeroallergen 7 5.2 Physical Irritants 7 5.3 Environmental Factors 7 5.4 Food 8 5.5 Microbial Colonisation/Infection 8 5.6 Patient Factors 8 6. TOPICAL THERAPY 9 6.1 Emollient/Moisturiser 9 6.2 Topical Corticosteroids 11 6.3 Topical Calcineurin Inhibitors 13 6.4 Wet Wrap Therapy 14 6.5 Other Topical Therapy 15 7. PHOTOTHERAPY (...) 16Management of Atopic Eczema TABLE OF CONTENTS No. Title Page 8. SYSTEMIC THERAPY 17 8.1 Antihistamines 17 8.2 Immunomodulating Agents 17 8.3 Biologics 20 8.4 Other Systemic Agents 22 9. ANTIMICROBIALS 23 9.1 Topical Antibiotics Combined with Corticosteroids 23 9.2 Systemic Antibiotics 23 9.3 Sodium Hypochlorite 0.005% (Bleach Bath) 23 9.4 Other Antiseptics 24 10. SPECIFIC ALLERGEN IMMUNOTHERAPY 25 11. NON-PHARMACOLOGICAL INTERVENTIONS 26 11.1 Bathing Practices 26 11.2 Dietary Interventions 26 11.3

2019 Ministry of Health, Malaysia

113. Contraceptive Choices for Young People

with a higher estrogen content. Co-cyprindiol (Dianette ® ) is indicated to treat severe acne that has not responded to oral antibiotics. In those with less severe symptoms it should be withdrawn 3-4 months after the condition has resolved. For women with known hyperandrogenism, longer use with specialist review may be warranted. Young people should be advised that the progestogen-only implant may be associated with improvement, worsening or onset of acne. Mood Changes and Depression Young people may (...) improve acne and thus can be considered in those who require contraception. Overall, few differences have been found between COC types in terms of their effectiveness for treating acne. 72 In the UK, co-cyprindiol (Dianette ® ) 73,74 should not be used solely for contraception and is licensed for treatment of severe acne that has not responded to oral antibiotics. Ideally it should be withdrawn 3–4 months after the condition has resolved. However, for women with known hyperandrogenism, longer use may

2019 Faculty of Sexual & Reproductive Healthcare

114. Chronic Asthma

) Identify Risks for Exacerbation # (worsening symptoms and lung function necessitating treatment adjustment) ? Poor perception of control ? Exacerbation within last year ? Comorbid rhinosinusitis, chronic lung disease, confirmed food allergy, pregnancy, obesity ? Environmental irritants ? FEV1 1 canister/month) ? OCS: current or recent use, or adverse effects ? Non-adherence 1 /lack of written Asthma Action Plan ? Emergency department or hospitalisation in last year or delayed presentation to hospital (...) ? Ever intubated or in critical care ? Cardiovascular disease ? Severe psychiatric/psychosocial issues Discuss Triggers 6 ? Cold air, thunderstorm ? Airborne irritants: smoke (1 st and 2 nd hand exposure), fuel combustion, odours, renovation, occupation-related ? Mould and pollens ? Dander especially from cat, dog ? Allergies, including peanut, seafood ? Food additives (sulphites, MSG); cold drinks ? Bee products, echinacea ? NSAIDs, ?-blockers, Aspirin ? Hormonal ? Exercise ? Extreme emotions

2018 Toward Optimized Practice

115. The economic evaluation of early intervention with Anti-Tumor Necrosis Factor-? treatments in pediatric Crohn's disease

of Anti-TNF-a Treatments. 72 Table 2.5.7.1.1-2. Costs and Doses of Immunomodulators. 74 Table 2.5.7.1.1-3. Costs and Doses of Corticosteroids. 76 Table 2.5.7.1.1-4. Costs and Doses of Antibiotics. 79 Table 2.5.7.1.1-5. Costs and Doses of Oral 5-ASA Drugs. 81 Table 2.5.7.1.1-6. Cost and Dose of Enteral Nutrition Brands. 83 Table 2.5.7.1.2-1. Medical Procedure Costs for CD Patients. 86 Table 2.5.7.1.2-2. Costs for Adverse Events of Special Interest and Surgical Complications. 87 xi Table 2.5.7.1.2-3 (...) . 244 Table A13-1. The weighted average cost of antibiotics per week and per weight for the standard care and early anti-TNF-a intervention comparator groups. 245 xiii Table A14-1. The weighted average cost of oral 5-ASA’s per week and per weight for the standard care and early anti-TNF-a intervention comparator groups. 246 Table A15-1. The age-dependent mean weekly cost of enteral nutrition supplements for males. 247 Table A15-2. The age-dependent mean weekly cost of enteral nutrition supplements

2019 SickKids Reports

116. Renal Transplantation

during laparoscopic donor nephrectomy: review of the FDA database. Urology, 2009. 74: 142. 21. Hsi, R.S., et al. Mechanisms of hemostatic failure during laparoscopic nephrectomy: review of Food and Drug Administration database. Urology, 2007. 70: 888. 22. Ponsky, L., et al. The Hem-o-lok clip is safe for laparoscopic nephrectomy: a multi-institutional review. Urology, 2008. 71: 593. 23. Allen, M.B., et al. Donor hemodynamics as a predictor of outcomes after kidney transplantation from donors after (...) the surgical risk in renal transplantation: A case-control study. Nephrol Dial Transplant, 2014. 29: 463. 87. Osman, Y., et al. Necessity of Routine Postoperative Heparinization in Non-Risky Live-Donor Renal Transplantation: Results of a Prospective Randomized Trial. Urology, 2007. 69: 647. 88. Orlando, G., et al. One-shot versus multidose perioperative antibiotic prophylaxis after kidney transplantation: a randomized, controlled clinical trial. Surgery, 2015. 157: 104. 89. Choi, S.U., et al. Clinical

2019 European Association of Urology

117. BSG consensus guidelines on the management of inflammatory bowel disease in adults

inhibitor, tofacitinib, therapeutic drug monitoring, anti-drug antibodies, nutrition, diet, vitamin D, anaemia, antibiotics, tuberculosis, TB, cytomegalovirus, CMV, clostridium difficile, cancer, chemoprevention, surveillance, pregnancy, fetus, breastfeeding, probiotic, antibiotic, faecal microbial transplant, vaccine, vaccination, multidisciplinary team, MDT, adherence, self-management, telephone clinic, virtual clinic, primary stress, care, shared care, fatigue, stress, psychology, psychotherapy (...) ultrasound 67 4.1.3.2 Detection of active disease 68 4.1.3.3 Investigation of strictures 68 4.1.3.4 Radiation exposure 69 4.1.3.5 Capsule Endoscopy 69 4.1.3.6 Balloon-assisted enteroscopy 71 4.2 Induction of remission in mild to moderate disease ileocolonic disease 71 4.2.1 Budesonide in ileocaecal Crohn’s disease 71 4.2.2 Corticosteroids in colonic Crohn’s disease 72 4.2.3 Nutritional therapy 72 4.2.3.1 Exclusive Enteral Nutrition (EEN) 72 4.2.3.2 Elimination diets 74 4.2.4 Antibiotic therapy 75 4.2.5

2019 British Society of Gastroenterology

118. Lumacaftor-ivacaftor (Orkambi) - cystic fibrosis

years or more. Lumacaftor 100mg, ivacaftor 125mg: two tablets twice daily in patients aged 6 to 11 years. Lumacaftor 150mg, ivacaftor 188mg granules: one sachet twice daily in patients aged 2 to 5 years who weigh 14kg or more. Lumacaftor 100mg, ivacaftor 125mg granules: one sachet twice daily in patients aged 2 to 5 years who weigh less than 14kg. Lumacaftor-ivacaftor should be taken with fat-containing food. A fat-containing meal or snack should be consumed just before or just after dosing (...) . The tablets should be swallowed whole and not broken, dissolved or chewed. The entire contents of a granule sachet should be mixed with one teaspoon (5 mL) of age-appropriate soft food or liquid and the mixture completely consumed within one hour. Lumacaftor-ivacaftor should only be prescribed by physicians with experience in the treatment of cystic fibrosis. If the patient’s genotype is unknown, an accurate and validated genotyping method should be performed to confirm the presence of the F508del

2019 Scottish Medicines Consortium

119. Tezacaftor-ivacaftor (Symkevi) - cystic fibrosis

with fat-containing food. The dose of tezacaftor-ivacaftor and ivacaftor should be adjusted when co-administered with moderate and strong CYP3A inhibitors. Patients should be instructed to swallow the tablets whole. The tablets should not be chewed, crushed, or broken before swallowing. Food or drink containing grapefruit or Seville oranges should be avoided during treatment. Tezacaftor-ivacaftor should only be prescribed by physicians with experience in the treatment of cystic fibrosis (...) disease progression but will still experience the severe symptoms of cystic fibrosis and premature mortality. 2 Current treatment of cystic fibrosis is based on supportive care targeting the symptoms of the disease and may include antibiotics, mucolytics, bronchodilators, corticosteroids, enzyme and nutritional supplements. CFTR modulators target the underlying defect in the CFTR protein. 2 Ivacaftor monotherapy is licensed for the treatment of cystic fibrosis in patients aged two years and older who

2019 Scottish Medicines Consortium

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>